D. Tichy

发表

Prediction of malignancy by a radiomic signature from contrast agent‐free diffusion MRI in suspicious breast lesions found on screening mammography.

Michael Götz, Manuel Wiesenfarth, Sebastian Bickelhaupt, 2017, Journal of magnetic resonance imaging : JMRI.

Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla

M. Roethke, T. Kuru, M. Fenchel, 2014, European Radiology.

Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.

H. Schlemmer, D. Bonekamp, W. Wick, 2016, Neuro-oncology.

Ago-RIP-Seq identifies Polycomb repressive complex I member CBX7 as a major target of miR-375 in prostate cancer progression

D. Heckmann, G. Kristiansen, M. Falkenstein, 2016, Oncotarget.

Acute Toxicity and Quality of Life in Patients With Prostate Cancer Treated With Protons or Carbon Ions in a Prospective Randomized Phase II Study--The IPI Trial.

K. Herfarth, B. Hadaschik, H. Schlemmer, 2016, International journal of radiation oncology, biology, physics.

Long-term ovarian function in women treated with CHOP or CHOP plus etoposide for aggressive lymphoma.

M. Ziepert, M. Pfreundschuh, S. Dietrich, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Erratum to: Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla

M. Roethke, T. Kuru, M. Fenchel, 2014, European Radiology.

Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial

H. Goldschmidt, A. Jauch, Y. Ko, 2021, Leukemia.

Antibiotic Prophylaxis or Granulocyte-Colony Stimulating Factor Support in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

H. Goldschmidt, A. Benner, E. Klein, 2021, Cancers.

Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trial.

H. Goldschmidt, E. Nievergall, T. Holderried, 2022, The Lancet. Haematology.

Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (I-KRd) in front-line treatment of high-risk Multiple Myeloma: Results of the Safety Run-In cohort in the phase II, multicenter GMMG-CONCEPT trial

H. Goldschmidt, C. Bokemeyer, A. Benner, 2019, Clinical Lymphoma Myeloma and Leukemia.

Parenthood in long‐term survivors after CHOP with or without etoposide treatment for aggressive lymphoma

M. Ziepert, M. Pfreundschuh, A. Ho, 2014, British journal of haematology.

Targeting atypical protein kinase C iota reduces viability in glioblastoma stem‐like cells via a notch signaling mechanism

P. Lichter, T. Hielscher, J. Bohlen, 2016, International journal of cancer.

First Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 705 Adults with Newly Diagnosed Acute Lymphoblastic Leukemia/Lymphoma (ALL/LBL)

K. Spiekermann, F. Schneller, H. Serve, 2021, Blood.

Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial

D. Hose, H. Goldschmidt, A. Jauch, 2020, Leukemia.

Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial

D. Hose, H. Goldschmidt, A. Jauch, 2021, Cancers.

Body fat composition as predictive factor for treatment response in patients with newly diagnosed multiple myeloma – subgroup analysis of the prospective GMMG MM5 trial

H. Kauczor, H. Goldschmidt, S. Delorme, 2017, Oncotarget.

Addition of Isatuximab to Lenalidomide, Bortezomib and Dexamethasone As Induction Therapy for Newly-Diagnosed, Transplant-Eligible Multiple Myeloma Patients: The Phase III GMMG-HD7 Trial

H. Goldschmidt, E. Nievergall, T. Holderried, 2021, Blood.

Performance Evaluation of MHC Class-I Binding Prediction Tools Based on an Experimentally Validated MHC–Peptide Binding Data Set

Diana Tichy, Maria Bonsack, Jan Winter, 2019, Cancer Immunology Research.

Predictive factors for immediate continence after radical prostatectomy

B. Hadaschik, D. Teber, S. Pahernik, 2015, World Journal of Urology.

Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6.

I. Herr, D. Tichy, J. Fellenberg, 2016, Cancer letters.

Dose Reduced Chemotherapy in Sequence with Blinatumomab for Newly Diagnosed Older Patients with B-Precursor Adult Lymphoblastic Leukemia (ALL): Results of the Ongoing GMALL Bold Trial

D. Tichy, B. Hertenstein, M. Brüggemann, 2021, Blood.

Depth of Response to Isatuximab, Carfilzomib, Lenalidomide and Dexamethasone (Isa-KRd) in Front-Line Treatment of High-Risk Multiple Myeloma: Interim Analysis of the GMMG-CONCEPT Trial

H. Goldschmidt, A. Jauch, Y. Ko, 2021, SSRN Electronic Journal.

Diffusion‐weighted MRI treatment monitoring of primary hypofractionated proton and carbon ion prostate cancer irradiation using raster scan technique

K. Herfarth, H. Schlemmer, D. Bonekamp, 2017, Journal of magnetic resonance imaging : JMRI.

Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome

H. Goldschmidt, A. Jauch, S. Haas, 2022, Blood.

Measured Multipoint Ultra-High b-Value Diffusion MRI in the Assessment of MRI-Detected Prostate Lesions

A. Stenzinger, T. Kuder, H. Schlemmer, 2020, Investigative radiology.

Complete bladder neck preservation promotes long-term post-prostatectomy continence without compromising midterm oncological outcome: analysis of a randomised controlled cohort

S. Pahernik, M. Hohenfellner, D. Tichy, 2018, World Journal of Urology.

Experimental design and data analysis of Ago‐RIP‐Seq experiments for the identification of microRNA targets

Axel Benner, Diana Tichy, Julia Maria Anna Pickl, 2018, Briefings Bioinform..

Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Newly Diagnosed Multiple Myeloma

A. Jauch, Y. Ko, C. Scheid, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P930: ISATUXIMAB, LENALIDOMIDE, BORTEZOMIB AND DEXAMETHASONE AS INDUCTION THERAPY FOR NEWLY-DIAGNOSED MULTIPLE MYELOMA PATIENTS WITH HIGH-RISK CYTOGENETICS: A SUBGROUP ANALYSIS FROM THE GMMG-HD7 TRIAL

Michael J. Hoffmann, E. Nievergall, J. Dürig, 2022, HemaSphere.